Open AccessResearch on the development of cancer drugs for children
Author(s) -
Yihan Wang
Publication year - 2021
Publication title -
e3s web of conferences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.203
H-Index - 22
eISSN - 2555-0403
pISSN - 2267-1242
DOI - 10.1051/e3sconf/202130802014
Subject(s) - legislation , government (linguistics) , cancer drugs , cancer , drug development , medicine , business , pediatric cancer , drug , family medicine , pharmacology , political science , philosophy , linguistics , law
The development of pediatric cancer drugs is inefficient and must requires a significant development to improve the current situation. According to the research on the development of pediatric cancer drugs, the market condition is analyzed and compared with adult cancer drugs. It is found that even though the drug market for pediatric cancer is significantly smaller than adult cancer’s drug market, it is still important that pediatric cancer drugs are developed in order to better serve the treatment for childhood cancer, and increase the survival rate for malign cancer cases. Through thorough research it also appeared that while the government provides some beneficial programs and insurances for children experiencing pediatric cancer, better insurance plans should be identified. Another important finding throughout research results in the government and legislation area, where the pediatric cancer drugs development process is analysed and has found some potential for the future. As a whole, the effort of the government in both the drug development period and the legislation area with the combination of big pharmaceutical companies’ efforts and the potential creation of new kinds of insurances, the situation for pediatric cancer drugs development can experience a positive change.